相关实验视频

Updated: Jul 25, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

在临床I期肺腺癌中表皮生长因子受体突变的预后影响

Fujun Yang¹, Ke Sun², Fei Li³

¹Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.

The Annals of thoracic surgery

|June 23, 2023

概括

皮表皮生长因子受体 (EGFR) 突变与临床第一阶段肺腺癌患者的纯固体瘤的无复发生存率较差有关. 这一发现对于地面玻璃结节患者来说有所不同,突出了预后影响的关键区别.

科学领域:

在瘤学瘤学.
分子诊断学分子诊断学
胸部外科手术胸部外科手术

背景情况:

肺腺癌是癌症死亡的一个重要原因.
皮表皮生长因子受体 (EGFR) 突变是肺癌的关键瘤原因.
了解EGFR突变在早期疾病的预后影响对于治疗分层至关重要.

研究的目的:

为了研究EGFR突变在临床第一阶段肺腺癌患者的预后影响.
确定EGFR突变状态是否影响无复发生存率 (RFS) 和整体生存率 (OS).
根据瘤成像特征分析这些影响,特别是纯固体外观与地面玻璃结节 (GGNs).

主要方法:

对952名经过切除的临床I期肺腺癌患者的回顾性分析.
检测瘤驱动突变,包括EGFR.
使用卡普兰-梅尔分析和日志等级测试估计RFS和OS.
考克斯的比例危险模型和竞争性风险回归被用来评估预后因素.

主要成果:

在61.0%的患者中发现了EGFR突变,女性,非吸烟者和患有GGN的人更常见.
在整体队列和GGN亚组中,EGFR突变与复发或死亡无关.
对于具有纯固体瘤外观的患者,EGFR突变独立预测了更糟糕的RFS和远期复发的增加,但不是OS.

结论:

在临床I期肺腺癌患者中,EGFR突变是复发和远程转移的独立风险因素,患者具有纯固体瘤外观.
EGFR突变的预后意义根据瘤成像特征 (纯固体与GGN) 不同.
这些发现强调了将成像特征与分子数据相结合的重要性,以便在早期肺腺癌中准确预测.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...